NDRG2 and breast carcinoma: In more detail, stratification of breast cancer specimen in triple negative (n = 24), luminal-type (n = 87) and HER2-enriched (n = 27) breast cancers showed a pronounced downregulation of NDRG2 in luminal-type and HER2-enriched tumors (P<0.001) compared to triple negative cancers (P = 0.025) (Fig 2C).